Global Retinal Biologics Market Research 2024, Forecast To 2033
8 Mar, 2024
The retinal biologics market has seen rapid growth, reaching $22.48 billion in 2023 and expected to grow to $25.45 billion in 2024, at a CAGR of 13.2%. This growth is attributed to increased incidence of retinal disorders and evolving healthcare infrastructure. Looking ahead, the market is forecasted to reach $39.69 billion in 2028, with a CAGR of 11.7%, driven by expanding therapeutic applications and government initiatives. Major trends include non-invasive delivery methods and regulatory pathway streamlining.
Global Retinal Biologics Market Key Driver
The retinal biologics market is poised for growth due to the increasing prevalence of diabetic eye disease worldwide. Diabetic eye disease, a complication of diabetes, poses a significant threat to vision, affecting millions globally. Retinal biologics offer precise and effective treatment options for diabetic retinopathy, allowing for early intervention and improved outcomes. For example, research by the American Medical Association reveals alarming statistics in the United States, highlighting the urgent need for advanced treatments to address diabetic eye disease and drive growth in the retinal biologics market.
Get A Free Sample Of The Global Retinal Biologics Market ReportGlobal Retinal Biologics Market Segments
The retinal biologics market covered in this report is segmented –
1) Drug Class:Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor
2) Indication:Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications
3) Distribution Channel:Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels
By Geography: The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the retinal biologics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Retinal Biologics Industry Players
Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co Inc; AbbVie Inc.; Bayer AG; Janssen Biotech; Novartis AG; Fresenius SE; AstraZeneca plc; Boehringer Ingelheim International GmbH.; Amgen Inc; Teva Pharmaceuticals Industries Ltd.; Bristol-Myers Squibb; Regeneron Pharmaceuticals Inc; Sun Pharmaceutical Industries Ltd.; Sanofi Genzyme; Bausch & Lomb; Santen Pharmaceutical Co. Ltd.; Swedish Orphan Biovitrum; Ocular Therapeutix; Alimera Sciences; Adverum Biotechnologies Inc.; MeiraGTx Limited; Oxurion NV; Graybug Vision Inc.; Kodiak Sciences Inc.; Clearside Biomedical Inc.; UCBCares; Allergan plc; Genentech Inc.; Iveric bio Inc.; Neurotech Pharmaceuticals Inc.; Opthea Limited
Get The Full Global Retinal Biologics Market Report
Retinal Biologics Market Overview
Retinal biologics refers to bioengineered macromolecules that are implanted inside the eyes to heal chronic retinal diseases. They are highly precise inflammatory mediator-targeting compounds used to treat inflammatory, corneal, and retinal medical conditions.